Sage Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Highlights Pipeline and Business Progress

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to Sage Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Highlights Pipeline and Business Progress

SAGE Therapeutics (SAGE) Tops Q4 EPS by $18.54, Revenues Beat

February 24, 2021 6:39 AM EST

SAGE Therapeutics (NASDAQ: SAGE) reported Q4 EPS of $18.19, $18.54 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $1.1 billion versus the consensus estimate of $55.34 million.

Reported positive interim data from Phase 3 open-label SHORELINE Study showing that more than 70% of patients successfully treated with zuranolone 30 mg needed two or fewer treatment courses over one yearProgressed WATERFALL Study now closed to... More